VJHemOnc Podcast iwAL 2022 Session V: mechanisms of resistance to targeted therapies in AML
Dec 6, 2022
Naval Daver and Paresh Vyas discuss mechanisms of resistance to targeted therapies in AML, including the impact of small clones and non-cell intrinsic effects. They explore the modulation of leukemia by therapies and the potential of using companion diagnostics and immunotherapies to predict long-term responders. The podcast also highlights the importance of testing for flip three mutation in AML patients and the role of epigenetic targets in therapy resistance.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Mechanisms of Resistance in IDH and Flit3 Mutant AML
01:38 • 4min
Early Modulation of Leukemia and Predicting Long-Term Responders
05:52 • 2min
Testing for Flip Three Mutation in AML Patients and its Significance in Treatment
08:09 • 2min
Mechanisms of Resistance to Targeted Therapies in AML
10:28 • 2min